Zevra Therapeutics shares are trading lower after the company announced the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency adopted a negative opinion regarding the Marketing Authorization Application for arimoclomol for the treatment of Niemann-Pick disease type C.